BioCardia FDA Accepts Helix Catheter De Novo Pre-Submission
BioCardia announced FDA acceptance of its revised submission for the Helix catheter, marking the start of substantive review expected this quarter. The approval paves the way for expanded partnerships related to heart disease therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed